Addition of spironolactone in patients with resistent arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F11%3A00102104" target="_blank" >RIV/00843989:_____/11:00102104 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >10.1161/HYPERTENSIONAHA.111.169961</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Addition of spironolactone in patients with resistent arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

Popis výsledku v původním jazyce

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP > 140 mm Hg or diastolic BP > 90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n = 59) or a placebo (n = 58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95% CI -10.0; -0.8) for systolic BP (P = 0.024

Název v anglickém jazyce

Addition of spironolactone in patients with resistent arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

Popis výsledku anglicky

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP > 140 mm Hg or diastolic BP > 90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n = 59) or a placebo (n = 58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95% CI -10.0; -0.8) for systolic BP (P = 0.024

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hypertension

ISSN

0194-911X

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1069-1075

Kód UT WoS článku

000290710800017

EID výsledku v databázi Scopus

—